Skin Cancer

A comprehensive analysis of 71 studies revealed the highest lesion clearance and recurrence rates among individuals who had undergone surgery.

Despite high accuracy scores, the study found AI models often produce overly complex explanations, making them less effective for patient education.

The overall reduction of tumor size in all lesions treated in part 2 was approximately 86%.

To improve overall outcomes for patients with large basal cell carcinomas, it has been beneficial to employ the use of vismodegib as a neoadjuvant and/or adjuvant treatment.

Researchers emphasized the need for improved reliability and regulatory frameworks for AI tools before they are integrated into dermatological practice.

Jacob Scott, MD, president and chairman of DaRT, shares highlights of the guidelines and what he hopes clinicians can glean from them.

In combination with cemiplimab, BNT111 contributed to statistically significant and improved overall response rates.

Researchers noted how historical bias in dermatology research has impacted the understanding and treatment of conditions in darker skin.

Margins < 1 mm also do not increase the risk of cutaneous squamous cell carcinoma recurrence risk if the galea aponeurotica is not involved.

Renata Block, MMS, PA-C, interviews dermatology clinicians and the Melanoma Research Foundation CEO at the Chicago SPF Fest.

The guidelines for BCC and SCC treatment with IGSRT detail diagnosis, staging, contraindications, protocols, and emphasize the essential role of a multidisciplinary team.

Michelle Bolas and Rukiyah T. Van Dross-Anderson, PhD, discuss the significance of NCInnovations’ funding and the clinical impact of Van Dross-Anderson's research in patients with advanced melanoma.

Adewole Adamson, MD, MPP, discusses the Environmental Working Group's 2024 Guide to Sunscreens and what clinicians should discuss with patients who express concerns with the headlines stemming from the report.

A recent study offers a comprehensive analysis of practice patterns and patient characteristics in different clinical settings.

Peter Prieto, MD, MPH, shares details of the IOV-COM-202 trial.

The most significant independent predictors of adherence to dermatology follow-up appointments were younger age and previous outpatient visits.

During the 2024 American Society of Clinical Oncology annual meeting, a poster highlighted the advantages Medicaid expansion could offer to individuals with melanoma.

Patricia Richey, MD, delves into efficacy of the 1927 and 1550 nanometer lasers to prevent skin cancers.

Cutaneous and advanced stage melanomas present significant challenges during pregnancy, according to the posters.

To address the increased rates of skin cancer while keeping unique patient needs top of mind, there is a pressing need to increase options for treatment.

What's the preferred sunscreen and why? Renata Block, MMS, PA-C, talks to the attendees of the 2024 SDPA Annual Summer Dermatology Conference.

Zabinski, vice president and head of commercial strategy and AI at OM1, discusses the evolving role of AI in dermatology, focusing on its potential and challenges in skin cancer detection.

Phase 3 trials have been initiated in patients with high-risk melanoma.

Earlier this week, we shared our fourth and final Skin Cancer Awareness Month quiz. Review the answers and your responses below.

Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month.

Earlier this week, we shared our third Skin Cancer Awareness Month quiz. Review the answers and your responses below.

The new action date is December 29, 2024.

While MMS is recognized as the gold standard for skin cancer treatment, numerous challenges still hinder widespread adoption and practice.

Andrew Baker, MBA, MPAS, PA-C, discusses his role in skin cancer detection and advice for PAs interested in skin surgeries and Mohs closures.

In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.